Transmigration of PBMNCs from β-IFN-1b-treated MS patients: A one-year longitudinal study

M. Gelati, E. Corsini, A. Dufour, M. Zaffaroni, C. Milanese, L. La Mantia, G. Massa, A. Salmaggi

Research output: Contribution to journalArticlepeer-review

Abstract

To evaluate the effects of in vivo β-IFN-1b treatment on transmigration of mononuclear cells, we monitored for one year in vitro mononuclear cells trafficking through HUVECs monolayers stratified over a collagen gel during β-IFN-1b treatment of 7 RR MS patients. The number of transmigrated cells was analysed before treatment (T0) and after 3 (T3), 6 (T6) and 12 months (T12); at the same time, levels of serum MMP-9 were quantified. The number of transmigrated cells decreased during treatment compared to pre-treatment values: the lowest number of transmigrated cells was detected at T3, and, although transmigration was still lower at T12, there was a trend to a return to pre-treatment levels over time. The amount of MMP-9 also decreased during therapy, although we could not find an absolute correlation between transmigration and levels of MMP-9, nor between either parameter and the clinical course of patients.

Original languageEnglish
Pages (from-to)275-283
Number of pages9
JournalAutoimmunity
Volume33
Issue number4
Publication statusPublished - 2001

Keywords

  • β-IFN
  • MMP-9
  • Multiple sclerosis
  • Transmigration

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Transmigration of PBMNCs from β-IFN-1b-treated MS patients: A one-year longitudinal study'. Together they form a unique fingerprint.

Cite this